Straits Times Index
3,320.30 +12.40 (+0.37%) Nikkei
39,082.31 +465.21 (+1.20%) Hang Seng
18,847.13 -348.47 (-1.82%) FTSE 100
8,370.33 -46.12 (-0.55%) Bitcoin USD
69,409.88 -526.67 (-0.75%) CMC Crypto 200
1,510.98 +8.31 (+0.55%)
Scinai Immunotherapeutics Ltd. (SCNI)
After hours:
| Previous close | 3.7900 |
| Open | 3.2400 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 3.2400 - 3.7499 |
| 52-week range | 3.1950 - 22.7000 |
| Volume | |
| Avg. volume | 3,454 |
| Market cap | 1.999M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -16.0000 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 390.00 |
PR NewswireScinai Publishes FY 2023 Financial Statements, Files Annual Report on Form 20-F and Provides Business Update
Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and on providing CDMO services through its Scinai Bioservices business unit, today published its full-year financial results for the year ended December 31, 2023, and provided a business update.
- PR Newswire
Scinai Immunotherapeutics Announces Receipt of Nasdaq Delisting Notification and Appeal
Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and on providing CDMO services through its Scinai Bioservices business unit, today announced that it had had received a staff determination letter (the "Letter") on April 30, 2024 from the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that, due to the Company's non-compliance with t
- PR Newswire
Scinai to showcase its novel biological local therapeutic for Plaque Psoriasis at Dermatology Drug Development Summit together with Prof. Michael Schön of UMG
Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and on providing CDMO services through its Scinai Bioservices business unit, today announced that the company's Chief Science Officer, Dr. Tamar Ben-Yedidia, and the University Medical Center Göttingen's Director, Department of Dermatology, Venereology & Allergology, Prof. Michael Schön, will be presenting together at the upcoming 5th Dermatology
